Abstract
Acridine derivatives are interesting chemotherapeutic agents that were first used as antibacterial and antiparasite agents. In this review we wish to concentrate our attention on the anticancer properties of acridines used in clinics since the 1970s. Based on recent results, an outlook on antitumour acridine chemotherapy will be proposed. The biological activity of acridines is mainly attributed to the planarity of these aromatic structures, which can intercalate within the double-stranded DNA structure, thus interfering with the cellular machinery. Recent understanding of the mode of action of acridines leads to continuous and exciting research in this heterocyclic family. Indeed, biological targets such as topoisomerases I and II, telomerase/telomere and protein kinases emerge and allow the design of novel acridine-based patterns. This review further pinpoints the latest progress in the development of anticancer agents based on naturally occurring and synthetic acridines (e.g. acridones, pyridoacridines); for this matter in vitro/in vivo studies and clinical trial results will be discussed. The DNA-affinic property of acridine is also useful to vectorise drugs into cell nuclei and some applications in hypoxia-selective treatment, platinum or N-mustard derived conjugates will be reported. Some other properties including inhibition of multidrug resistance or potential impact on Alzheimer disease will be treated. It is noteworthy that the position and the nature of the substituent on the heterocyclic core are determinants for the biological property and selectivity observed. So, we wish also to disclose a summary of recent synthetic methodologies developed for acridine synthesis.
Keywords: Acridine, acridone, alkaloid, anticancer, antitumour, topoisomerases, telomerase, hypoxia, organic synthesis
Anti-Cancer Agents in Medicinal Chemistry
Title: Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?
Volume: 7 Issue: 2
Author(s): Philippe Belmont, Johann Bosson, Thomas Godet and Martin Tiano
Affiliation:
Keywords: Acridine, acridone, alkaloid, anticancer, antitumour, topoisomerases, telomerase, hypoxia, organic synthesis
Abstract: Acridine derivatives are interesting chemotherapeutic agents that were first used as antibacterial and antiparasite agents. In this review we wish to concentrate our attention on the anticancer properties of acridines used in clinics since the 1970s. Based on recent results, an outlook on antitumour acridine chemotherapy will be proposed. The biological activity of acridines is mainly attributed to the planarity of these aromatic structures, which can intercalate within the double-stranded DNA structure, thus interfering with the cellular machinery. Recent understanding of the mode of action of acridines leads to continuous and exciting research in this heterocyclic family. Indeed, biological targets such as topoisomerases I and II, telomerase/telomere and protein kinases emerge and allow the design of novel acridine-based patterns. This review further pinpoints the latest progress in the development of anticancer agents based on naturally occurring and synthetic acridines (e.g. acridones, pyridoacridines); for this matter in vitro/in vivo studies and clinical trial results will be discussed. The DNA-affinic property of acridine is also useful to vectorise drugs into cell nuclei and some applications in hypoxia-selective treatment, platinum or N-mustard derived conjugates will be reported. Some other properties including inhibition of multidrug resistance or potential impact on Alzheimer disease will be treated. It is noteworthy that the position and the nature of the substituent on the heterocyclic core are determinants for the biological property and selectivity observed. So, we wish also to disclose a summary of recent synthetic methodologies developed for acridine synthesis.
Export Options
About this article
Cite this article as:
Belmont Philippe, Bosson Johann, Godet Thomas and Tiano Martin, Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/187152007780058669
DOI https://dx.doi.org/10.2174/187152007780058669 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Astaxanthin, the Natural Antioxidant, Reduces Reserpine Induced Depression in Mice
Current Bioactive Compounds The Endocannabinoid System: A New Molecular Target for the Treatment of Tobacco Addiction
CNS & Neurological Disorders - Drug Targets Recent Patents on Molecular Cytogenetics
Recent Patents on DNA & Gene Sequences Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Can Probiotics Supplementation Improve Glycemic and Renal Status in Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Recombinant Human Growth Hormone in Abstinent Androgenic-Anabolic Steroid Use: Psychological, Endocrine and Trophic Factor Effects
Current Neurovascular Research DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Diet and Neurocognition in Mood Disorders - An Overview of the Overlooked
Current Pharmaceutical Design The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Editorial: Closing the Gap: Working Toward Effective Therapy for DIPGs
Current Neuropharmacology Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Review of the Syntheses and Activities of Some Sulfur-Containing Drugs
Current Organic Synthesis The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Overview of Systems Biology and Omics Technologies
Current Medicinal Chemistry 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery
Current Drug Metabolism Editorial [Hot Topic:Ion Channels as a Target for Drug Design (Executive Editor: Kwok-Keung Tai)]
Current Pharmaceutical Design Advances in Medicinal Plants with Effects on Anxiety Behavior Associated to Mental and Health Conditions
Current Medicinal Chemistry Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Synthesis of Coenzyme Q10
Current Organic Chemistry